Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome

Hemoglobin

Volumn 28, Issue 2, 2004, Pages 85-102

  Ballas, Samir K ^a   Files, Beatrice ^b   Luchtman Jones, Lori ^c   Benjamin, Lennette ^d   Swerdlow, Paul ^e   Hilliard, Lee ^f   Coates, Thomas ^g   Abboud, Miguel ^h   Wojtowicz Praga, Slawomir ⁱ   Grindel, J Michael ^j  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f CHILDREN S HOSPITAL   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ SANOFI   (France)

^j CytRx Corporation   (United States)

more..

Author keywords

Acute chest syndrome (ACS); Flocor; Purified poloxamer 188; Sickle cell anemia; Surfactant

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; HYDROXYUREA; NONIONIC SURFACTANT; POLOXAMER;

ACUTE CHEST SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG PURIFICATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GAIT DISORDER; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SICKLE CELL ANEMIA; SIDE EFFECT;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY; LUNG DISEASES; MALE; POLOXAMER; SURFACE-ACTIVE AGENTS; SYNDROME;

EID: 2442655317     PISSN: 03630269     EISSN: None     Source Type: Journal    
DOI: 10.1081/HEM-120035919     Document Type: Article

References (38)

1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639-1644.
2. Sprinkle RH, Cole T, Smith S, Buchanan GR. Acute chest syndrome in children with sickle cell disease: a retrospective analysis of 10 hospitalized cases. Am J Pediatr Hematol/Oncol 1986; 8:105-110.
3. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci EA, National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000; 342:1855-1865.
4. Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, McQuitty J. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994; 83:3107-3112.
5. Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Curr Opin Hematol 1998; 5:89-92.
6. Vichinsky E. Transfusion therapy. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH., eds. Sickle Cell Disease. Basic Principles and Clinical Practice. New York: Raven Press, 1994:781-794.
7. Olivieri NF. Clinical effectiveness of chelating therapy, Presented at Current Biochemistry to New Chelator Development Strategies, September 21-22, 1998; National Institutes of Health: Bethesda, MD.
8. Carr ME, Powers PL, Jones MR. Effects of poloxamer 188 on the assembly, structure and dissolution of fibrin clots. Thromb Haemost 1991; 66:565-568.
9. Carter C, Fisher TC, Hamai H, Johnson CS, Meiselman HJ, Nash GB, Stuart J. Haemorheological effects of a nonionic copolymer surfactant (Poloxamer 188). Clin Hemorheol 1992; 12:109-120.
10. McKenna R, Cole E, MacLeod C, Emanuele M, Hunter R. The effects of RheothRx on platelet function and coagulation in man. Blood 1989; 74:411.
11. Grover FL, Kahn RS, Heron MW, Paton BC. A nonionic surfactant and blood viscosity. Arch Surg 1973; 106:307-310.
12. Schaer GL, Spaccavento LJ, Browne KF, Krueger KA, Krichbaum D, Phelan JM, Fletcher WO, Grines CL, Edwards S, Jolly MK, Gibbons RJ. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 1996; 94:298-307.
13. O'Keefe JH, Grines CL, DeWood MA, Schaer GL, Browne L, Magorien RD, Kalbfleisch JM, Fletcher WO Jr, Bateman TM, Gibbons RJ. Poloxamer 188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 78:747-750.
14. Maynard C, Swenson R, Paris JA, Martin JS, Hallstrom AP, Cerqueira MD, Weaver WD. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. Am Heart J 1998; 135:797-804.
15. Yusuf S, for the Collaborative Organization for RheothRx Evaluation (CORE). Effects of RheothRx on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. Circulation 1997; 96:192-201.
16. Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease. JAMA 2001; 286:2099-2106.
17. Casella JF, Wojtowicz-Praga S, Grindel JM. A Phase III multicenter, randomized, double-blind, placebo-controlled study of FLOCOR (purified poloxamer 188) in patients with sickle cell disease in acute vaso-occlusive crisis. Presented at the 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia, PA, April 9-12, 2000.
18. Casella JF, Watanabe M, Files B, Shafer F, Luchtman-Jones L, Wun T, Emanuele M, Grindel JM. FLOCOR's efficacy and safety in pediatric sickle cell patients experiencing acute vaso-occlusive crisis: a subgroup analysis. Blood 2000; 96:9a.
19. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, Crawford R, Edward S, Bustrack J, Emanuele M. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997; 90:2041-2046.
20. Luchtman-Jones L, Files B, Ballas SK, Swerdlow P, Benjamin L, Hilliard L, Coates T, Abboud M, Wojtowicz-Praga S, Grindel JM. Phase I study of FLOCOR in patients with acute chest syndrome of sickle cell disease. Blood 1999; 94:25b.
21. Jewell RC, Khor SP, Kisor DF, LaCroix KAK, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers. J Pharm Sci 1997; 86:808-812.
22. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997; 89:1787-1792.
23. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, Vera JC, Levy PS. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643-649.
24. Koren A, Wald I, Halevi R, Ben Ami M. Acute chest syndrome in children with sickle cell anemia. Pediatr Hematol Oncol 1990; 7:99-107.
25. Miller ST, Hammerschlag MR, Chirgwin K, Rao SP, Roblin P, Gelling M, Stilerman T, Schachter J, Cassell G. Role of chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr 1991; 118:30-33.
26. Godeau B, Schaeffer A, Bachir D, Fleury-Feith J, Galacteros F, Verra F, Escudier E, Vaillant JN, Brun-Buisson C, Rahmouni A, Allaoui AS, Lebargy F. Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome. Value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med 1996; 153: 1691-1696.
27. Lowenthal EA, Wells A, Emanuel PD, Player R, Prchal JT. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol 1996; 51:207-213.
28. Rucknagel DL, Kalinyak KA, Gelfand MJ. Rib infarcts and acute chest syndrome in sickle cell disease. Lancet 1991; 337:831-833.
29. Gelfand MJ, Daya SA, Rucknagel DL, Kalinyak KA, Paltiel HJ. Simultaneous occurrence of rib infarction and pulmonary infiltrates in sickle cell disease patients with acute chest syndrome. J Nucl Med 1993; 34:614-618.
30. Bhalla M, Abboud MR, McLoud TC, Shepard JA, Munden MM, Jackson SM, Beaty JR, Laver JH. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology 1993; 187:45-49.
31. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082-3089.
32. Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child 1998; 142:178-182.
33. Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M. Effect of transfusion in acute chest syndrome of sickle cell disease. J Pediatr 1995; 127:901-904.
34. Kress JP, Pohlman AS, Hall JB. Determination of hemoglobin saturation in patients with acute sickle chest syndrome: a comparison of arterial blood gases and pulse oximetry. Chest 1999; 115:1316-1320.
35. Emre U, Miller ST, Rao SP, Rao M. Alveolar-arterial oxygen gradient in acute chest syndrome of sickle cell disease. J Pediatr 1993; 123:272-275.
36. Bowen EF, Crowston JG, De Ceulaer K, Serjeant GR. Peak expiratory flow rate and the acute chest syndrome in homozygous sickle cell disease. Arch Dis Child 1991; 66:330-332.
37. Santoli F, Zerah F, Vasile N, Bachir D, Galacteros F, Atlan G. Pulmonary function in sickle disease with or without acute chest syndrome. Eur Respir J 1998; 12:1124-1129.
38. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood 1999; 94:1555-1560.